Risk of mortality in patients with cancer who experience febrile neutropenia (Q40351157)

19 September 2017

title

Risk of mortality in patients with cancer who experience febrile neutropenia (English)

1 reference

19 September 2017

Gary H Lyman

1

1 reference

19 September 2017

Shannon L Michels

2

1 reference

19 September 2017

Matthew W Reynolds

3

1 reference

19 September 2017

Rich Barron

4

1 reference

19 September 2017

Karen Smoyer Tomic

5

1 reference

19 September 2017

Jingbo Yu

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

16 August 2010

1 reference

19 September 2017

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

19 September 2017

volume

116

1 reference

19 September 2017

issue

23

1 reference

19 September 2017

page(s)

5555-5563

1 reference

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Risk models for predicting chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Management of fever in patients with cancer and treatment-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Dose-response effect of adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Risk assessment and treatment of low-risk patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

Epidemiology of febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Prevention and treatment of cancer-related infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Kinetics of mammary tumor cell growth and implications for therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Cost of neutropenic complications of chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25332

7 January 2021

Identifiers

DOI

10.1002/CNCR.25332

1 reference

19 September 2017

1 reference